5 Needs context
Approximately 55% of the current global human population is colonized with Helicobacter pylori.
"and something like 55% of the world's population at the moment has Helicobacter in their systems." (said at 0:45:00)
Historical global prevalence estimates for Helicobacter pylori infection frequently cited figures above 50%, with a 2017 meta-analysis concluding that more than half of the world's population was infected. However, updated global meta-analyses demonstrate a continuing decline in prevalence over recent decades. Between 2015 and 2022, global prevalence fell to approximately 43.9% in adults and 35.1% in children and adolescents. Therefore, while a figure near 55% reflects historical data, current global prevalence is estimated to be lower, between roughly 35% and 44%.
Approximately 15% of patients treated with triple antibiotic therapy for Helicobacter pylori cannot tolerate it or do not achieve eradication.
"to treat it with so-called triple therapy: three separate antibiotics, and kill it so you can't find it anymore. An alternative—and I should say about 15% of people who are given that treatment either can't take it or it doesn't work." (said at 0:46:40)
The statement bundles two distinct assertions: the composition of triple therapy and its failure/intolerance rate.
1. Regimen composition: Standard triple therapy for Helicobacter pylori infection does not consist of three separate antibiotics. Rather, it comprises one proton-pump inhibitor (an acid-suppressing medication) and two antibiotics (typically amoxicillin and clarithromycin, or metronidazole).
2. Failure and intolerance rates: The claim that approximately 15% (or more) of patients fail eradication or experience intolerance is well-supported by systematic reviews and meta-analyses of randomized trials. Intention-to-treat eradication rates for standard triple therapy range from 75% to 82% (representing an eradication failure rate of 18% to 25%), while adverse event rates are reported at roughly 19.5% to 20.4%.
A study found that approximately 70% of dietary supplements on the market do not contain their labeled contents or stated concentrations.
"I think there was even a study showing something like 70% of, like, a lot of these supplements on the market are not actually what they say they are. They don't have the concentrations they say." (said at 0:39:15)
Multiple analytical investigations of dietary supplements have identified substantial rates of mislabeling, absence of declared active ingredients, and marked discrepancies between labeled and measured concentrations. However, such findings derive from targeted investigations of specific high-risk or niche categories (such as sports performance botanicals, cognitive enhancers, or herbal formulations) rather than a single definitive audit demonstrating that approximately 70% of all dietary supplements across the broader market are mislabeled. In sampled categories, inaccurate active ingredient concentrations and complete absence of labeled compounds occur frequently.
In men with prostate cancer, high doses of sulforaphane slowed the PSA doubling rate by 86%.
"And one study is showing that men with prostate cancer that were given pretty relatively high doses of sulforaphane, it slowed their doubling rate of the PSA by 86%." (said at 2:15:10)
A double-blind, randomized controlled trial of 78 men with biochemically recurrent prostate cancer after radical prostatectomy (Cipolla et al., 2015) evaluated daily oral administration of 60 mg of sulforaphane for 6 months. The study found that the prostate-specific antigen (PSA) doubling time was 86% longer in the sulforaphane group compared to the placebo group (28.9 months vs. 15.5 months). However, lengthening doubling time by 86% mathematically corresponds to an approximate 46% decrease in doubling rate, not an 86% reduction in rate. Furthermore, the trial's primary endpoint (a predefined reduction in the log PSA slope) was not statistically met, although secondary endpoints favored sulforaphane.
Bernard Cipolla conducted a clinical trial in France demonstrating a significant reduction in PSA trajectory in prostate cancer patients using the supplement Prostaphane.
"and Bernard Cipolla in France, using actually that supplement. Cipolla's study used—where he showed a dramatic reduction in the trajectory of PSA numbers, used—what's it called? Prostaphane." (said at 2:15:35)
Bernard Cipolla and colleagues conducted a double-blind, randomized, placebo-controlled multicenter clinical trial in France evaluating 60 mg/day of stabilized free sulforaphane (Prostaphane) in 78 men with biochemical recurrence following radical prostatectomy. Although the trial's prespecified primary endpoint (a decrease in log PSA slope) was not statistically met, secondary endpoints demonstrated a substantial slowing of PSA progression: the PSA doubling time was extended by 86% compared with placebo (28.9 months vs. 15.5 months), and the mean increase in PSA over 6 months was significantly smaller in the sulforaphane group (+0.099 ng/mL vs. +0.620 ng/mL, p = 0.0433).
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.